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Hyperglycemia and Diabetes in Patients
With Schizophrenia or Schizoaffective
Disorders
DAN COHEN, MD1,2
RONALD P. STOLK, MD, PHD2,3
DIEDERICK E. GROBBEE, MD, PHD2
CHRISTINE C. GISPEN-DE WIED, MD, PHD4
OBJECTIVE— Pharmacoepidemiological studies have shown an increased prevalence of
diabetes in patients with schizophrenia. To address this issue, we decided to assess glucose
metabolism in a population of patients with schizophrenia or schizoaffective disorder.
RESEARCH DESIGN AND METHODS— Oral glucose tolerance tests (OGTTs) were
performed in 200 unselected in- and outpatients. Insulin sensitivity and -cell function were
assessed using the homeostasis model assessment (HOMA) indexes and 30-min glucose and
insulin levels.
RESULTS— The mainly Western European (87.7%) study population had a mean age of 40.8
years, was 70% male, and had a mean fasting glucose of 5.1 mmol/l and a mean fasting insulin
of 14.8 mU/l. Hyperglycemia was present in 7% of the population: 1.5% with impaired fasting
glucose and 5.5% with impaired glucose tolerance. The prevalence of diabetes was 14.5%, of
which 8% was previously known and 6.5% was newly diagnosed. Compared with a 1.5%
prevalence of diabetes in the age-matched general Dutch population, the prevalence of identified
cases was significantly increased in the study population. Comparable figures on the prevalence
of hyperglycemia in the general population are not available. Insulin resistance was increased in
the study population as a whole (HOMA of insulin resistance: 3.1–3.5), irrespective of the use of
antipsychotic medication and, if used, irrespective of its type (typical or atypical). No indication
of -cell defect was found, whereas a nonsignificant increased insulin resistance was found with
antipsychotic medication.
CONCLUSIONS— OGTTs in 200 mainly Caucasian patients with schizophrenia or schizo-
affective disorder, mean age 41 years, showed that 7% suffered from hyperglycemia and 14.5%
from diabetes. The prevalence of diabetes was significantly increased compared with the general
population. No differential effect of antipsychotic monotherapy in diabetogenic effects was
found. Therefore, a modification of the consensus statement on antipsychotic drugs, obesity, and
diabetes is proposed, i.e., measurement of fasting glucose in all patients with schizophrenia,
irrespective of prescribed antipsychotic drug.
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The first description of disturbancesof the glucose metabolism in schizo-phrenic patients dates from 1879
(1) and was confirmed by many authors
(2–6) in the first half of the 20th century.
The introduction of neuroleptics was ac-
companied by a rapid increase in type 2
diabetes in these patients. Numerous case
reports and epidemiological studies (7–
12) have shown an increased rate of
disturbed glucose metabol ism in
hospitilized patients treated with neuro-
leptics. The atypical or second-generation
antipsychotic drugs, introduced in the
1990s, showed less extrapyramidal side-
effects but seemed to have a stronger dia-
betogenic effect than the classical
antipsychotics. The pathophysiologic
mechanism of the disturbing glucose me-
tabolism is not well known.
Pharmacoepidemiological research of
large databases has recently been the main
focus of research (13–22), with two clear
methodological restrictions (23). First,
database studies are based on an estab-
lished clinical diagnosis of diabetes,
whereas it is known that especially in the
care of patients with schizophrenia a sub-
stantial proportion of diabetic patients is
undiagnosed (19). Second, database
studies are unable to shed light on the
etiology of glucose intolerance because of
lack of information on the preclinical
phase of disturbed glucose metabolism,
i.e., hyperglycemia.
We decided to investigate the preva-
lence of impaired glucose tolerance and di-
abetes and the differences that can be
attributed to the type of antipsychotic med-
ication in patients with schizophrenia and
schizoaffective disorder using the oral glu-
cose tolerance test (OGTT). Glucose and in-
sulin were measured during the test. Insulin
sensitivity and-cell function were assessed
using the homeostasis model assessment
(HOMA) indexes and 30-min glucose and
insulin levels.
RESEARCH DESIGN AND
METHODS— The research protocol
was approved by the medical ethical com-
mission of the University of Utrecht. Partic-
ipants between the ages of 18 and 65 years
were recruited from the mental health care
organizations Rijngeestgroep (Oegstgeest,
Voorhout, Noordwijkerhout) and De Grote
Rivieren (Dordrecht) and Anoiksis, the
Dutch organization for patients with schizo-
phrenia. After providing written informed
consent, the M.I.N.I. Plus (24), a structured
diagnostic interview for DSM-IV (Diagnos-
tic and Statistical Manual of Mental Disor-
ders, 4th edition) diagnosis, and the
available medical records were used for a
DSM-IV diagnosis of schizophrenia or
schizoaffective disorder.
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A 75-g OGTT was performed, with
venous plasma measurements of glucose
and insulin at 15, 0, 30, 60, and 120
min. In patients with diagnosed diabetes,
only a fasting blood sample was taken.
Glucose was determined by the Synchron
Clinical System (Beckmann Coulter),
with a detection limit of 0.3–38.8 mmol/l.
The coefficient of variation varied be-
tween 2 and 3% at different levels. Serum
insulin was measured by radioimmunoas-
say (Medgenix, Fleurus, Belgium), with a
detection limit of 3 mU/l. The coefficient
of variation varied between 3.8 and 7.6%
at different levels.
Impaired fasting glucose was diag-
nosed when the mean fasting glucose
plasma level at t  15 and t  0 was
between 6.1 and 7.0, with a glucose level
at t  120 7.8 mmol/l. Impaired glu-
cose tolerance was diagnosed when the
plasma glucose levels at t 120 were be-
tween 7.8 and 11.1 mmol/l. Diabetes
was defined as a mean fasting glucose
7.0 mmol/l and/or a glucose level at t
12011.1 mmol/l (25). HOMA was used
to assess insulin sensitivity and -cell
function, based on fasting insulin and glu-
cose levels and according to published al-
gorithms: HOMA resistance (insulin
glucose)/22.5 and HOMA -cell func-
tion 20 insulin/(glucose 3.5) (26).
-Cell function was further studied using
the 30-min glucose and insulin level dur-
ing the OGTT. The prevalence of glucose
intolerance as well as the results of the
OGTT are presented as means  SD and
compared between different subgroups of
patients. Linear regression and ANCOVA
were used to adjust these differences for
potential confounders, notably age, sex,
BMI, and waist-to-hip ratio. The differ-
ence between types of antipsychotic med-
ications was also analyzed using linear
regression. All analyses were performed
using SPSS for Windows 11.5.
We expected that the use of typical and
atypical antipsychotics would be about
equal in these patients. To detect a differ-
ence of fasting plasma glucose 0.5 mmol/l,
two groups of 101 patients are needed (SD
1.0, two-sided  0.05, power 0.85).
RESULTS
Descriptives
Most participants of the study were re-
cruited from the semirural part of the
Dutch province Zuid-Holland. A total of
87.7% of the study population was of
Western European origin, with the re-
maining 12.3% equally divided between
the Asian, African, Mediterranean, and
Hindustan population. Nearly two-thirds
(64%) of the participants were outpa-
tients; the remaining 35.4% was equally
divided over the different forms of more
intensive psychiatric care: supported liv-
ing (11.1%), sheltered living (10.6%),
and inpatients (13.6%) (Table 1).
Twelve patients, currently not using
antipsychotic medication, had signifi-
cantly lower BMI and waist-to-hip ratios
(25.3 vs. 28.2 kg/m2, 0.87 vs. 0.95, re-
spectively; both comparisons P  0.05
adjusted for age and sex). Of the remain-
ing 188 patients, 182 used antipsychotic
monotherapy and 6 antipsychotic poly-
pharmacy: two typical antipsychotic
drugs (n 2) or a combination of typical
and atypical agents (n  4).
Patients were classified as on typical
(n  55) and atypical (n  133) medica-
tion, the latter including the four patients
with classical plus atypical drugs. The two
groups did not differ in age, BMI, or waist-
to-hip ratio (all comparisons P  0.4 ad-
justed for age and sex).
Glucose metabolism
Before every OGTT, the fasting status of
the patient was confirmed. In the cases
where the patient was not fasting, the
OGTT was canceled and a new appoint-
ment was made. In the study population
(n  200), we found 157 patients
(78.5%) with normoglycemia, 14 (7%)
with hyperglycemia, and 29 (14.5%) with
diabetes (Table 1). No significant differ-
ences were found by sex (P 0.39), psy-
chiatric diagnosis (P  0.197), or
psychiatric setting (P  0.24) (Table 1).
Further subdivision of hyperglycemia
showed impaired fasting glucose present
in 4 patients (2%) and impaired glucose
tolerance in 11 patients (5.5%). Diabetes
was an established diagnosis in 16 pa-
tients (8%) and newly diagnosed in 13
patients (6.5%).
Insuline resistance and -cell
function
The fasting values of glucose and insulin
levels as well as HOMA estimates for the
whole study population are presented in
Table 2. There were no differences be-
tween men and women (P  0.39).
Higher age was associated with increased
plasma glucose and HOMA of insulin re-
sistance values (P  0.05). The glucose
and insulin levels during the OGTT are
presented in Fig. 1.
Table 1—Demographic variables by glucose metabolism
Classification Normal Impaired fasting glucose Impaired glucose tolerance Diabetes P value
Schizophrenia 135 (78.5%) 3 (2.3%) 11 (6.4%) 22 (12.8%) 0.197
Schizoaffective disorder 20 (74.1%) 0 (0%) 0 (0%) 7 (25.9%)
Male 113 (80.7%) 3 (2.1%) 7 (5.0%) 17 (12.1%) 0.39
Female 44 (73.3%) 0 (0%) 4 (6.7%) 12 (20%)
Inpatient 24 (88.9%) 0 (0%) 0 (0%) 3 (11.1%) 0.24
Outpatient 98 (76.6%) 1 (0.8%) 8 (6.3%) 21 (16.4%)
Supported living 17 (77.3%) 1 (4.5%) 2 (9.1%) 2 (9.1%)
Sheltered living 16 (72.2%) 2 (9.1%) 1 (4.5%) 3 (13.6%)
Total 157 (78.5%) 4 (1.5%) 11 (5.5%) 29 (14.5%)
Data are n patients (proportion). P values are adjusted for age and sex, if appropriate.
Table 2—Clinical characteristics of the study
population
Characteristics
Age 40.8  10.2
BMI (kg/m²) 28.1  5.2
Waist-to-hip ratio 0.95  0.08
Fasting glucose (mmol/l) 5.1  1.1
Fasting insulin (mU/l) 14.8  16.7
HOMA of -cell function 192  730
HOMA of insulin resistance 3.4  4.0
Data are means  SD.
Cohen and Associates
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Antipsychotic medication
After adjustment for age and sex, fasting
glucose, insulin, and HOMA estimates were
not associated with type of antipsychotic
medication (Table 3). Further adjustment
for BMI or waist-to-hip ratio did not change
the results. The prevalences of disturbed
glucose levels for the individual atypical pa-
tients were as follows: patients with hyper-
glycemia: clozapine 18% (7 of 39),
olanzapine 2.3% (1 of 44), quetiapine 0%
(0 of 5), and risperidone 11.6% (5 of 43);
patients with diabetes: clozapine 12.8% (5
of 39), olanzapine 18.2% (8 of 44), quetia-
pine 0% (0 of 5), and risperidone 16.3% (7
of 43). After excluding patients currently
not using antipsychotic medication (“no
AP”), the difference did not reach statistical
significance (P 0.2).
The first-phase insulin response,
measured by 	30 (Table 3) and graphi-
cally presented in Fig. 1, was the same in
all patients, irrespective of their treatment
modality. Patients using antipsychotic
medications had (nonsignificant) in-
creased insulin levels during the second
half of the OGTT, which was more pro-
nounced in those using atypical drugs.
Figure 1—Glucose and insulin levels during the OGTT by antipsychotic drug use. Error bars indicate SE.
Table 3—Antipsychotic medication and glucosemetabolism on OGTT
No AP Classic Atypical P value
n 12 52 136
Fasting glucose (mmol/l) 4.8  0.4 5.1  1.1 5.1  1.1 0.65
Fasting insulin (mU/l) 8.2  3.7 14.6  16.4 15.7  18.0 0.99
HOMA of -cell function 222  306 173  388 197  849 0.95
HOMA of insulin
resistance
3.1  4.8 3.5  4.5 3.4  3.7 0.95
	ins30/glu30 22.76  31.13 28.76  33.52 18.00  30.92 0.73
Normoglycemia 10 (83.3) 43 (82.7) 103 (75.5) 0.741
Hyperglycemia 1 (8.3) 2 (3.8) 12 (8.8)
Diabetes 1 (8.3) 7 (13.5) 21 (15.4)
Data are means  SD or n (%). P values are adjusted for age and sex. AP, antipsychotic medication.
Hyperglycemia and schizophrenia
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CONCLUSIONS— In accordance
with the recommendations by the World
Health Organization, we used the OGTT
to assess the glucose regulation in our
cross-sectional study. In 200 mainly Cau-
casian patients with schizophrenia or
schizoaffective disorder, hyperglycemia
was found to be present in 7% and diabe-
tes in 14.5% of this relatively young pop-
ulation. Impaired fasting glucose
accounted for 1.5% of the hyperglycemia
and impaired glucose tolerance for the re-
maining 5.5%. The 14.5% with diabetes
consisted of 8% previously known and
6.5% newly diagnosed cases.
The results reveal that the less severe
form of glucose metabolism (hyperglyce-
mia) was less prevalent (7%) compared
with the 14.5% with the more severe form
(diabetes). This result seems to confirm
earlier findings that disturbance of glu-
cose metabolism tends to be more severe
in patients with schizophrenia than in the
general population (27,28). The differ-
ences in prevalence of impaired fasting
glucose (1.5%) and impaired glucose tol-
erance (5.5%) reflect the differences in
sensitivity between fasting and 2-h mea-
surements.
The prevalence of previously known
diabetes in our study population with a
mean age of 41 years (8%) is comparable
with the prevalence in the general Dutch
population 20 years older, in the age-
group 60–65 years (29). This suggests
that an early aging effect is present in the
population of patients with schizophrenia
or schizoaffective disorder.
When we turn to the hypothesis, i.e.,
the absence of an effect of the class of an-
tipsychotic medication on glucose metab-
olism, we see that both in absolute terms
(means of fasting glucose, insulin level,
HOMA of -cell function, and HOMA of
insulin resistance; Table 3) and in relative
terms (distribution of the three possible
outcomes of the OGTT; Table 3), no dif-
ference between the two classes of medi-
cation was found, thereby confirming the
hypothesis. The results of Fig. 1 suggest
that antipsychotic drugs increase periph-
eral insulin resistance in patients with
schizophrenia.
As far as the power of the study is
concerned, the study may have been
slightly underpowered, but the lack of
difference in absolute terms between
means and percentages indicates that no
small differences were missed. The design
therefore did not effect the results in a
negative way. The result of this study dif-
fers from some (30 –33) but confirms
other (34–36) studies in patient popula-
tions. Ha¨gg et al. (30) found no significant
difference in the prevalence of hypergly-
cemia or diabetes between patients on
typical antipsychotic medication or cloza-
pine. The study is complicated by 19%
antipsychotic polypharmacy in the cloza-
pine group. In a study with four treatment
conditions, typical, clozapine, olanzap-
ine, and risperidone, and healthy control
subjects, Newcomer et al. (31) found a
significant increase of glucose levels for
olanzapine and clozapine in comparison
with typical antipsychotic and healthy
control subjects. Antipsychotic polyphar-
macy (15%), differences in treatment
duration (19 days to 1 year), different
distribution of BMI, and high-risk African
Amer i cans over the four
treatment conditions complicate the
interpretation of the results.
In a comparative, cross-sectional
study of BMI-matched, nonobese, stable
patients treated with atypical antipsy-
chotics (treatment duration not men-
tioned), Henderson et al. (32), using the
frequently sampled intravenous glucose
tolerance test, found significant impair-
ment of glucose effectiviness in patients
treated with olanzapine and clozapine
when compared with risperidone. No sig-
nificant differences in age or BMI were
reported. In a prospective study of pa-
tients treated with clozapine during 2–4
months, Howes et al. (34) found a signif-
icant increase of plasma glucose levels, in-
dependent of change in either insulin
resistance or BMI. In another study with
OGTT on three atypicals, Smith et al. (35)
failed to find a significant difference in 2-h
glucose between olanzapine, risperidone,
and clozapine. In these three studies, with
significant increase of glucose levels, the
small size (104 patients alltogether) and
high proportion of high-risk African
Americans (varying between 17 and 83%)
preclude any definite conclusions.
The results of the prospective study
by Lindenmayer et al. (33) might be in-
dicative of the influence of treatment du-
ration on study outcome. In a comparison
of haloperidol with the atypicals cloza-
pine, olanzapine, and risperidone, a sig-
nificantly raised glucose level was found
at 8 weeks in the clozapine and haloperi-
dol groups. After an extension of 6 weeks,
the increased glucose level was only
found in a third group of olanzapine.
Recently, it was suggested that
screening for diabetes in hospitalized pa-
tients is more intensive when atypical an-
tipsychotics are prescribed (37). This may
explain the higher prevalence of diabetes
found with these atypical agents. The lack
of association between drug therapy and
disturbed glucose metabolism, both on a
group level (typical versus atypical) and
on the level of the individual atypical AP
in this study, seems to confirm 1) earlier
reports on increased prevalence of diabe-
tes in patients treated with typical anti-
psychotics (38–40), 2) clinical studies in
inpatients with schizophrenia (34 –
36,41) and bipolar and schizoaffective
disorders (42), and 3) two recently pub-
lished, long-term prospective 52-week
randomized studies: a double-blind trial
of clozapine versus chlorpromazine in
treatment-naive first-episode inpatients
(43) and an investigator-blinded parallel-
group comparison of flexible doses of hal-
operidol and quetiapine (44). Moreover,
due to the combination of a mixed in- and
outpatient study population with a strong
emphasis of 64% on the outpatient pop-
ulation, this study extends the results ob-
tained in inpatients to the majority, i.e.,
the outpatient population.
The patients in our study stem from
three different psychiatric settings: inpa-
tient care, outpatient care, and supported/
sheltered living, thereby covering the
whole spectrum of severity and disability
found in the population of patients suffer-
ing from schizophrenia or schizoaffective
disorder. We think, therefore, that the
study population, and its results, fairly
represents the Caucasian patient popula-
tion of the Netherlands.
With diabetes increasingly recog-
nized as a serious health problem in the
treatment of schizophrenia with the
second-generation antipsychotics, the
discussion on the health risks of antipsy-
chotic drugs is turning away from the
drug-related neurological motor side-
effects to, among other things, the endo-
crinological problem of disturbed glucose
metabolism. Irrespective of the uncer-
tainty that surrounds the still-open
question of the pathophysiological mech-
anisms involved (iatrogenic or endo-
genic), the implications are both distinct
and severe. The results of this study
clearly indicate the importance, if not ne-
cessity, of assessment of glucose metabo-
lism in patients with schizophrenia or
schizoaffective disorder. In case of doubt,
the OGTT is the more sensitive measure-
ment but in clinical practice is less feasible
then a fasting glucose.
The monitoring protocol of the con-
sensus development conference (45) re-
stricts fasting glucose measurement to
Cohen and Associates
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patients treated with atypical antipsy-
chotics. We suggest a modification of this
consensus to extend this measurement to
all patients with schizophrenia or schizo-
affective disorder, irrespective of the use
or type of antipsychotic drug applied.
Acknowledgments— This study was made
possible by unrestricted grants from Dr. Paul
Janssen Stichting (Tilburg) and Rijngeestgroep
(Oegstgeest).
We thank Peter Edelbroek, Hugo van En-
gelsdorp, Marijke Fro¨hlich, Karen Gehring,
Nil Kaymaz, Roel de Rijk, Jeannine Stelck, and
Tinie van der Tang for their contributions.
References
1. Maudsley H: The Pathology of Mind. 3rd
ed. London, Macmillan and Co, 1879, p.
113
2. Redlich E: Zur Frage der beziehungen
zwischen diabetes mellitus und Psycho-
sen. Wien Med Wochenschrift 53:1041–1046,
1903
3. Singer HD, Clark SN: Psychoses associ-
ated with diabetes mellitus. J Nerv Mental
Disease 46:421–428, 1917
4. Appel KE, Farr CB: The blood sugar reac-
tion to insulin in psychoses. Arch Neurol
Psychiatry 21:145–148, 1929
5. Menninger WC: The inter-relationship of
mental disorders and diabetes mellitus. J
Ment Sci 81:332–357, 1935
6. Freeman H: Resistance to insulin in men-
tally disturbed soldiers. Arch Neurol Psy-
chiatry 56:74–78, 1946
7. Charatan FBE, Bartlett NG: The effect of
chlorpromazine (“Largactil”) on glucose
tolerance. J Ment Sci 101:351–353, 1955
8. Hiles BW: Hyperglycemia and glycosuria
following chlorpromazine therapy. JAMA
162:1651, 1956
9. Waitzkin L: A survey for unknown diabet-
ics in a mental hospital. 1. Men under age
fifty. Diabetes 15:97–104, 1966
10. Waitzkin L: A survey for unknown dia-
betics in a mental hospital. 2. Men from
age fifty. Diabetes 15:164–172, 1966
11. Thonnard-Neumann E: Phenothiazines
and diabetes in hospitalized women. Am J
Psychiatry 124:138–142, 1968
12. Amdisen A: Changes of the oral glucose
tolerance test during long-term treatment
with neuroleptics. Acta Psychiatr Scand
203:95–96, 1968
13. Lund BC, Perry PJ, Brooks JM, Arndt S:
Clozapine use in patients with schizo-
phrenia and the risk of diabetes, hyperlip-
idemia, and hypertension. Arch Gen
Psychiatry 58:1172–1176, 2001
14. Kornegay CJ, Vasilakis-Scaramozza C,
Jick HJ: Incident diabetes associated with
antipsychotic use in the United Kingdom
general practice research database. J Clin
Psychiatry 63:758–762, 2002
15. Koro CE, Fedder DO, L’Italien GJ, Weiss
SS, Magder LS, Kreyenbuhl J, Revicki DA,
Buchanan RW: Assessment of indepen-
dent effect of olanzapine and risperidone
on risk of diabetes among patients with
schizophrenia: population based nested
case-control study. BMJ 325:243–247,
2002
16. Wang PS, Glynn RJ, Ganz DA, Schnee-
weiss S, Levin R, Avorn J: Clozapine use
and risk of diabetes mellitus. J Clin Psycho-
pharmacol 22:236–243, 2002
17. Gianfrancesco F, White R, Wang RH,
Nasrallah HA: Antipsychotic-induced
type 2 diabetes: evidence from a large
health plan database. J Clin Psychopharma-
col 23:328–335, 2003
18. Gianfrancesco FD, Grogg AL, Mahmoud
RA, Wang RH, Nasrallah HA: Differential
effects of risperidone, olanzapine, cloza-
pine and conventional antipsychotics on
type 2 diabetes: findings from a large
health plan database. J Clin Psychiatry 63:
920–930, 2002
19. Sernyak MJ, Leslie DL, Alarcon RD,
Losonzcy MF, Rosenheck R: Association
of diabetes mellitus with use of atypical
neuroleptics in the treatment of schizo-
phrenia. Am J Psychiatry 159:561–566,
2002
20. Lamberti JS, Crilly JF, Maharaj K, Olson
D, Wiener K, Dvorin S, Oana Costea G,
Bushey MP, Dietz MB: Prevalence of dia-
betes mellitus among outpatients with se-
vere mental disorders receiving atypical
antipsychotic drugs. J Clin Psychiatry 65:
702–706, 2004
21. Sumiyoshi T, Roy A, Anil AE, Jayathilake
K, Ertugrul A, Meltzer HY: A comparison
of incidence of diabetes mellitus between
atypical antipsychiotic drugs. J Clin Psy-
chopharmacology 24:345–348, 2004
22. Lee DW, Fowler RB, Kadlubek PJ, Haber-
man M: No significant difference in di-
abtes risk during treatment with typical
versus atypical antipsychotics: results
from a large observational study. Drug
Benefit Trends 14:46–52, 2002
23. Citrome LL: The increase in risk of diabe-
tes mellitus from exposure to second-gen-
eration antipsychotic agents. Drugs Today
40:445–464, 2004
24. Sheehan DV, Lecubrier Y, van Vliet IM,
Leroy H, van Megen HJGM: M.I.N.I. Plus.
M.I.N.I. Internationaal Neuropsychiatrisch
Interview. Nederlandse Versie 5.0.0. Utrecht,
the Netherlands, University of Utrecht,
2000
25. World Health Organization: Definition,
Diagnosis and Classification of Diabetes mel-
litus and Its Complication. Part 1: Diagnosis
and Classification of Diabetes Mellitus. De-
partment of Noncommunicable Disease
Surveillance, Geneva, World Health Org.,
1999
26. Matthews DR, Hosker JP, Rudenski AS,
Naylor BA, Treacher DF, Turner RC: Ho-
meostasis model assess ment: insulin re-
sistance and beta-cell function from
fasting plasma glucose and insulin con-
centrations in man. Diabetologia 28:412–
419, 1985
27. Spoelstra JA, Stolk RP, Cohen D, Klungel
OH, Erkens JA, Leufkens HGM, Grobbee
RE: Antipsychotic drugs may worsen met-
abolic control in type 2 diabetes mellitus.
J Clin Psychiatry 65:674–678, 2004
28. Cohen D, Batstra M, Gispen-de Wied CC:
Immunological characteristics of diabetes
mellitus in schizophrenia. Diabetologia
48:1941–1942, 2005
29. Gijsen R, Baan CA, Feskens EJM. Hoe
vaak komt diabetes mellitus voor en
hoeveel mensen sterven eraan? [arti-
cle online], 2004. Available at http://
www.rivm.nl/vtv/object_document/
01259n17502.html. Accessed on 13 May
2005
30. Ha¨gg S, Joelsson L, Mjo¨rndal T, Spigset O,
Oja G, Dahlqvist R: Prevalence of diabetes
and impaired glucose tolerance in pa-
tients treated with clozapine compared
with patients treated with conventional
depot neuroleptic medications. J Clin Psy-
chiatry 59:294–299, 1998
31. Newcomer JW, Haupt DW, Fucetola R,
Melson AK, Schweiger JA, Cooper BP,
Selke G: Abnormalities in glucose regula-
tion during antipsychotic treatment of
schizophrenia. Arch Gen Psychiatry
59:337–345, 2002
32. Henderson DC, Cagliero E, Copeland PM,
Borba CP, Evins E, Hayden D, Weber MT,
Anderson EJ, Allison DB, Daley TB,
Schoenfeld D, Goff DC: Glucose metabo-
lism in patients with schizophrenia
treated with atypical antipsychotic agents.
Arch Gen Psychiatry 62:19–28, 2005
33. Howes OD, Bhatnagar A, Gaughran FP,
Amiel SA, Murray RM, Pilowsky LS: A
prospective study of impairment in glu-
cose control caused by clozapine without
changes in insulin resistance. Am J Psychi-
atry 161:361–363, 2004
34. Lindenmayer JP, Czobor P, Volavka J,
Citrome L, Sheitman B, McEvoy JP, Coo-
per TB, Chakos M, Lieberman JA:
Changes in glucose and cholesterol levels
in patients with schizophrenia treated
with typical or atypical antipsychotics.
Am J Psychiatry 160:290–296, 2003
35. Smith RC, Lindenmayer JP, Bark N,
Warner-Cohen J, Vaidhyanathaswamy S,
Khandat A: Clozapine, risperidone, olan-
zapine, and conventional antipsychotic
drug effects on glucose, lipids, and leptin
in schizophrenic patients. Int J Neuropsy-
chopharmacol 8:183–194, 2005
36. Cohen D, Puite B, Dekker JJ, Gispen-de
Wied CC: Diabetes mellitus in 93 chronic
schizophrenic inpatients. Eur J Psychiatry
17:38–47, 2003
Hyperglycemia and schizophrenia
790 DIABETES CARE, VOLUME 29, NUMBER 4, APRIL 2006
37. Taylor D, Young C, Esop R, Paton C, Wal-
wyn R: Testing for diabetes in hospitalised
patients prescribed antipsychotic drugs.
Br J Psychiatry 185:152–156, 2004
38. Mukherjee S, Decina P, Bocola V, Saranc-
eni F, Scapicchio PL: Diabetes mellitus in
schizophrenic patients. Compr Psychiatry
37:68–73, 1996
39. Dixon L, Weiden P, Delahanty J, Gold-
berg R, Postrado L, Lucksted A, Lehman
A: Prevalence and correlates of diabetes in
national schizophrenia samples. Schizo-
phrenia Bull 26:903–912, 2000
40. Subramaniam M, Chong S-A, Pek E: Dia-
betes mellitus and impaired glucose toler-
ance in patients with schizophrenia. Can
J Psychiatry 48:345–347, 2003
41. Cohen D, Dekker JJ, Peen J, Gispen-de
Wied CC: Prevalence of diabetes mellitus
in chronic schizophrenic inpatients in re-
lation to long-term neuroleptic treatment.
Eur Neuropsychopharmacol (Epub ahead
of print)
42. Regenold WT, Thapar RK, Marano C,
Gavriuneni S, Kondapavuluru PV: In-
creased prevalence of type 2 diabetes mel-
litus among psychiatric inpatients with
bipolar affective and schizoaffective disor-
ders independent of psychotropic drugs. J
Affect Disord 70:19–26, 2002
43. Lieberman JA, Phillips M, Hongbin G,
Stroup S, Zhang P, Kong L, Zhongfu J,
Koch G, Hamer RM: Atypical and conven-
tional antipsychotic drugs in treatment-
naive first-episode schizophrenia: a 52-
week randomized trial of clozapine vs
chlorpromazine. Neuropsychopharmacol-
ogy 28:995–1003, 2003
44. Emsley R, Turner HJ, Schronen J, Botha
K, Smit R, Oosthuizen PP: Effects of
quetiapine and haloperidol on body mass
index and glycaemic control: a long-term,
randomized, controlled trial. Int J Neuro-
psychopharmacol 8:175–182, 2005
45. American Diabetes Association, American
Psychiatric Association, American Associ-
ation of Clinical Endocrinologists, North
American Association for the Study of
Obesity: Consensus development confer-
ence on antipsychotic drugs and obesity
and diabetes. Diabetes Care 27:596–601,
2004
Cohen and Associates
DIABETES CARE, VOLUME 29, NUMBER 4, APRIL 2006 791
